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Abstract: Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, 
known as statins, have revolutionized the treatment of hypercholesterolemia and coronary artery 
disease prevention. However, there are considerable issues regarding statin safety and further 
development of residual risk control, particularly for diabetic and metabolic syndrome patients. 
Pitavastatin is a potent statin with low-density lipoprotein (LDL) cholesterol-lowering effects 
comparable to those of atorvastatin or rosuvastatin. Pitavastatin has a high-density lipoprotein 
(HDL) cholesterol raising effect, may improve insulin resistance, and has little influence on 
glucose metabolism. Considering these factors along with its unique pharmacokinetic proper-
ties, which suggest minimal drug–drug interaction, pitavastatin could provide an alternative 
treatment choice, especially in patients with glucose intolerance or diabetes mellitus. Many 
clinical trials are now underway to test the clinical efficacy of pitavastatin in various settings 
and are expected to provide further information.
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Introduction
Statins can competitively inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase, resulting in an effective decrease of low-density lipoprotein (LDL) 
cholesterol levels, and their use has been proved to reduce major cardiovascular 
events in both primary and secondary prevention.1 Since 1973 when Akira Endo 
discovered the first statin, ML236B (compactin or mevastatin) in Japan, a variety 
of statins have been developed all over the world.2 Pitavastatin (LIVALO® Tablet) 
is a synthetic statin developed by Nissan Chemical Industries Ltd (Tokyo, Japan), 
and Kowa Co Ltd (Nagoya, Japan). In Japan, the usual dose of pitavastatin is 
1–2 mg/day, and the maximum dose is 4 mg/day. Pitavastatin appeared first on the 
Japanese market in September 2003, in Korea in July 2005, Thailand in January 
2008, China in July 2009, and the US in June 2010. Pitavastatin will appear on the 
European market in 2011.
Recently, the prevalence of diabetes mellitus has greatly increased in Japan as 
well as in other industrialized countries, and prevention of coronary artery disease 
in diabetics has become an emerging issue to be resolved. One of the character-
istics of patients with diabetes mellitus is impaired insulin secretion. Their beta 
cells cannot fully compensate for the insulin resistance caused by various environ-
mental factors, and therefore they easily fall into chronic insulin insufficiency. In 
this article, we review clinical evidence for the use of pitavastatin in the treatment 
of hypercholesterolemia and in the prevention of atherosclerotic cardiovascular Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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diseases, especially focusing on efficacy in patients with 
diabetes mellitus, who are an important target population 
for statin treatment.
Pharmacokinetic and 
pharmacodynamic properties
Pharmacokinetic properties
Pitavastatin is distributed selectively to the target organ, 
the liver, and pharmacokinetic studies in rats conducted 
using  14C-pitavastatin have confirmed approximately 
54 times greater radioactivity in the liver than in the serum3. 
  Pitavastatin is a lipophilic statin. Its bioavailability is about 
60%, tmax is 0.5–0.8 hours, t1/2 is 11 hours, and the urinary 
excretion rate of both pitavastatin and its lactone form are less 
than 2%. Pitavastatin shows enterohepatic circulation and is 
excreted with the feces. Pitavastatin is minimally metabolized 
by liver cytochrome P450 (CYP), which seems a favorable 
feature in terms of CYP-mediated drug–drug interaction. 
The CYP metabolic properties of pitavastatin are similar to 
those of pravastatin and rosuvastatin, and it is classified as 
a non-CYP metabolizable type (Table 1).4
Pharmacodynamic properties
Pitavastatin has a characteristic structure consisting of a 
heptenoate basic structure with a quinoline ring, moieties 
of fluorophenyl and a cyclopropyl side chain (Figure 1),5 
which provides optimal activity as a HMG-CoA reductase 
inhibitor and better drug absorption. Figure 2 shows simu-
lation imaging of the binding mode with the active site on 
the reductase.6 Pitavastatin inhibits HMG-CoA reductase 
and synthesis of cholesterol in the liver like other statins, 
however, the IC50 for the inhibition of cholesterol synthesis 
from [14C] acetic acid in the cultured human hepatoma cell 
line HepG2 was found to be 5.8 nM, being 2.9-fold higher 
than that of simvastatin and 5.7-fold higher than that of 
atorvastatin.7 The ED50 of oral pitavastatin for inhibition of 
sterol synthesis in the rat liver was 0.13 mg/kg, being 2.8-fold 
and 18-fold higher, respectively, than that of simvastatin and 
that of pravastatin.8
Clinical studies of pitavastatin
Efficacy
improvement of dyslipidemia
effects on LDL cholesterol
In the Steno-2 Study, intensive, multifactorial care of patients 
with type 2 diabetes led to reduction of rates of death and 
cardiovascular disorders.9,10 By contrast, in the ACCORD 
trial, intensive glucose lowering in type 2 diabetics increased 
mortality and did not significantly reduce major cardiovas-
cular events.11 In the ADVANCE trial, intensive glucose 
Table 1 Pharmacokinetic parameters of statins
Statin Pitavastatin Atorvastatin Fluvastatin Lovastatin Pravastatin Rosuvastatin Simvastatin
Molecular weight 881 1209 433.5 405 446.5 1001 418.15
Origin Synthetic Synthetic Synthetic Microbial Semi-synthetic 
(microbial origin)
Synthetic Semi-synthetic 
(microbial origin)
Racemic No No Yes No No No No
Prodrug No No No Yes No No Yes
Log P 1.49 1.11 1.27 1.70 −0.84 −0.33 1.60
Absorption (%) 80 30 98 31 37 50 65–85
Hepatic excretion (%) NA .70 68 .70 66 90 78–87
Bioavailability (%) .60 12 10–35 ,5 17 20 ,5
effect of food on 
bioavailability (%)
No Yes (↓ 13) Yes (↓ 15–25) Yes (↑ 50) Yes (↓ 30) No No
Protein binding (%) 96 .98 .98 96–98.5 43–54 88 .95
Tmax 0.5–0.8 2.0–4.0 0.5–1.5 2.8 0.9–1.6 3 1.3–2.4
T1/2 11 11–30 0.5–2.3 2.5–3.0 0.8–3.0 20 1.9–3.0
Renal excretion ,2 2 6 30 60 10 13
50% inhibitory 
concentration (nmol/L)
6.8 15.2 17.9 2.7–11.1 55.1 12 18.1
Lipid-lowering 
Metabolites
No Yes, active Yes, mainly 
inactive
Yes Yes, mainly  
active
No Yes
Range of dose (mg) 1–4 10–80 20–80 10–80 5–40 5–80 5–80
CYP isoforms 
primarily involved  
with metabolic pathway
CYP2C9 CYP3A4 CYP2C9 CYP3A4 CYP3A4 CYP2C9 CYP3A4
Minimally Minimally Minimally
Note: Log P, logarithm of base 10 of the n-octanol/water partition coefficient of active hydroxy forms of statins. 
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lowering in type 2 diabetic subjects significantly reduced the 
composite outcome of major macrovascular or microvascu-
lar events, but there was no significant reduction in major 
macrovascular events.12
Contrary to this controversy over the effects of intensive 
glucose lowering on cardiovascular events, the importance 
of the management of LDL cholesterol in diabetes mellitus 
has already been shown by many. In the United Kingdom 
prospective diabetes study (UKPDS 23)13 and the Japan 
Diabetes Complications Study (JDCS 9th),14 LDL cholesterol 
was the top-ranked risk factor for coronary artery disease 
in type 2 diabetes. The Cholesterol Treatment Trialists’ 
(CTT) collaborators reported the importance of LDL cho-
lesterol lowering therapy with statins in 18,686 people with 
  diabetes.15 Based on these findings, in the Japan Atheroscle-
rosis Society (JAS) Guideline, diabetic patients are classified 
as Category III (high-risk group) and their LDL cholesterol 
treatment goal is less than 120 mg/dL, or less than 100 mg/dL 
if they have coronary artery disease.16 In the United States, 
the consensus conference report from the ADA/ACC recom-
mended that the LDL cholesterol goal of the highest-risk 
patients, with established diabetes with one or more additional 
major cardiovascular disease risk factor, should be less than 
70 mg/dL.17 In the prevention of coronary artery diseases in 
diabetic patients, it may be important to pay attention not only 
to glycemic control but also to lipid profile.
To achieve these LDL cholesterol goals, intensive medi-
cation in which statins play a pivotal role is required. Six 
statins are currently available in the Japanese market and 
pitavastatin is one of the three potent statins. In the Japanese 
dose-response trial, the LDL cholesterol lowering effect of 
pitavastatin after 12 weeks was 34% (n = 81) at a dose of 
1 mg, 42% (n = 75) at a dose of 2 mg, and 47% (n = 76) at a 
dose of 4 mg.18 In the LIVES Study, a large-scale, prospec-
tive post-marketing surveillance of pitavastatin19 and the 
JAPAN-ACS study, a prospective, randomized, open-label, 
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Figure 1 Chemical structures of statins. The circled moiety on pitavastatin denotes the unique cyclopropyl group.
Adapted from Catapano.5
Figure 2 Pitavastatin in the complex with active site of human HMG-CoA reductase.
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Figure 3 Changes in LDL cholesterol before and after administration of pitavastatin 
2 mg/day in hyperlipidemic patients with and without type 2 diabetes mellitus.
Adapted from Nomura et al.21
parallel group study with blind endpoint evaluation at 33 
centers in Japan,20 the LDL cholesterol lowering effect among 
diabetic patients was almost the same as that in nondiabetic 
subjects. Nomura et al reported that 6 months administra-
tion of pitavastatin at 2 mg/day significantly reduced LDL 
cholesterol, from 155 to 88 mg/dL, in 45 diabetic patients 
(Figure 3).21 In the CHIBA Study, a randomized, multi-
centered, open-label study comparing the efficacy and safety 
of pitavastatin with that of atorvastatin in Japanese patients 
with hypercholesterolemia, 12 weeks administration of 
pitavastatin 2 mg/day (n = 126) significantly reduced LDL 
cholesterol by 42.6%, which was almost the same reduction 
produced by atorvastatin 10 mg/day (n = 125).22
In Europe, a randomized, double-blind, 12-week study to 
compare pitavastatin and simvastatin reported that the admin-
istration of pitavastatin 2 mg/day reduced LDL cholesterol 
by 39.0% (n = 307), which was significantly greater than 
that achieved with simvastatin 20 mg/day (35.0%, n = 107), 
and that the administration of pitavastatin 4 mg/day reduced 
LDL cholesterol by 44.0% (n = 319), which was compa-
rable to that of simvastatin 40 mg/day (42.8%, n = 110).23 
Another   European randomized, double-blind, comparative 
study reported that 12-week administration of pitavastatin 
2 mg/day reduced LDL cholesterol by 37.9% (n = 315), 
which was comparable to that of atorvastatin 10 mg/day 
(37.8%, n = 102), and that the administration of pitavastatin 
4 mg/day reduced LDL cholesterol by 44.6% (n = 298) which 
was comparable to that of atorvastatin 20 mg/day (43.5%, 
n = 102).24
High-density lipoprotein (HDL) cholesterol
Insulin resistance causes various dyslipidemic states such as 
increase of small dense LDL particles, remnant   lipoprotein, 
and decrease of HDL cholesterol. In diabetes mellitus, reduced 
activity of lipoprotein lipase (LPL) leads to low HDL choles-
terol because of impaired catabolism of VLDL.25 In addition, it 
has recently been reported that low HDL cholesterol in type 2 
diabetic patients is associated with   hypoadiponectinemia.26 
In diabetes mellitus, the management of low HDL choles-
terol is important. In the subanalysis of the J-LIT study, an 
increase of 10 mg/dL in HDL cholesterol was associated 
with a 34.9% decrease in the risk of coronary events in type 2 
diabetes.27
One of the most striking characteristics of pitavastatin 
is the HDL cholesterol increase which continues for about 
2 years from the start of administration. Pitavastatin 1–4 mg/
day significantly increased the serum HDL cholesterol lev-
els in a long-term (52 weeks) administration study.28 In the 
LIVES Study, 2-year treatment with pitavastatin 1–4 mg/day 
significantly increased serum HDL cholesterol levels from 
58.8 to 60.8 mg/dL (+5.9%) in all subjects (n = 3427) and 
from 35.1 to 43.3 mg/dL (+24.6%) in low HDL cholesterol 
(,40 mg/dL) subjects (n = 346) (Figure 4).29 In the PIAT 
Study to compare pitavastatin 2 mg/day (n = 88) and atorvas-
tatin 10 mg/day (n = 85), pitavastatin gave greater increases 
in HDL cholesterol and ApoA-1 levels than atorvastatin after 
1 year of treatment.30 In the European 1-year trial (n = 1346), 
pitavastatin 4 mg/day increased HDL cholesterol from 50.5 
to 57.0 mg/dL (+14.3%).31
The mechanisms of the increase of HDL cholesterol caused 
by pitavastatin have been reported by several investigators. In 
hepatocytes, pitavastatin increases ApoA-1 gene expression 
through the activation of peroxisome proliferator-activated 
receptor (PPAR)-α,32 which is considered a major regulator 
of intra- and extracellular fatty acid metabolism, and also 
increases ApoA-1 secretion by elevating ATP binding cassette 
A1 (ABCA1) expression via activation of LXRα.33 Although 
pitavastatin decreases circulating cholesterylester transfer 
protein (CETP) mass in hypercholesterolemic patients,34 
induction of ApoA-1 production may play a central role in 
increasing HDL cholesterol.30,35
Non-HDL cholesterol
Non-HDL cholesterol is easily calculated as: total cholesterol 
minus HDL cholesterol. The measurement of non-HDL 
cholesterol is reliable even in the nonfasting sample and is 
noted as the secondary target after the achievement of LDL 
cholesterol goals. The goal for non-HDL cholesterol has been 
reported to be the level of LDL cholesterol plus 30 mg/dL.36 
In type 2 diabetics, several characteristics such as elevated 
triglycerides, decreased HDL cholesterol, and elevated small Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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dense LDL, are well-known.25 Because non-HDL cholesterol 
reflects all apolipoprotein B-containing atherogenic lipo-
proteins, non-HDL cholesterol may be useful in predicting 
cardiovascular disease in patients with type 2 diabetes 
mellitus. In the Strong Heart Study, non-HDL cholesterol 
was a strong predictor of coronary heart disease in men and 
women with diabetes.37
In the CHIBA Study, the reduction of non-HDL choles-
terol by pitavastatin 2 mg/day (39.0%) was similar to that 
achieved with atorvastatin 10 mg/day (40.3%). However, in 
the atorvastatin group, the waist circumference, body weight 
and BMI were significantly correlated with percent reduc-
tion of non-HDL cholesterol, whereas pitavastatin showed 
consistent reduction of non-HDL cholesterol irrespective of 
these variables.22
Remnant lipoprotein, small dense LDL
Serum levels of remnant-like particle (RLP) cholesterol and 
small dense LDL are elevated in diabetic patients as a result 
of insulin resistance.38,39 RLP and small dense LDL are more 
susceptible to oxidation and in turn more atherogenic relative 
to LDL particles. Effects of pitavastatin on these specific 
lipoprotein particles are as follows.
In 28 diabetic patients, all of whom were treated with 
pitavastatin 2 mg/day for 8 weeks, LDL cholesterol signifi-
cantly decreased by 36.1% (from 168.4 to 105.4 mg/dL), 
small dense LDL significantly decreased by 10.3% (from 
29.9 to 19.7%), peak particle diameter of LDL significantly 
increased by 0.7 nm (from 26.363 to 27.095 nm), and RLP 
cholesterol significantly decreased by 2.49 mg/dL (from 
6.62 to 4.13 mg/dL).40 In another report, administration of 
pitavastatin 1 mg/day for 3 months significantly reduced 
small dense LDL from 37 to 25 mg/dL measured in type 2 
diabetic patients.41
vascular effect
In diabetics, vascular endothelial function can be impaired 
by hyperglycemia or oxidized lipoproteins.42,43
In Watanabe heritable hyperlipidemic myocardial 
infarction-prone rabbits (WHHL-MI rabbits), 8 week 
treatment with 0.5 mg/kg/day pitavastatin resulted in a sig-
nificant increase in acetylcholine induced nitric oxide (NO) 
production.44 The silent mating type information regulation 
2 homolog 1 (SIRT1) gene has been recognized as a key 
regulator of vascular endothelial homeostasis, controlling 
angiogenesis, endothelial senescence, and dysfunction. 
Administration of pitavastatin increased endothelial nitric 
oxide synthase (eNOS), SIRT1, and catalase expression 
and decreased endothelial senescence in streptozotocin-
diabetic mice.45 In clinical settings, pitavastatin 2 mg/day 
(n = 37) increased flow-mediated dilatation (FMD) more 
in comparison with atorvastatin 10 mg/day (n = 34) after 
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Figure 4 The time course of HDL cholesterol for 104 weeks before and after administration of pitavastatin 1–4 mg/day in the LiveS study.
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2 weeks treatment (relative change 82% vs 40%, P , 0.05).46 
In type 2 diabetic patients, administration of pitavastatin 
2 mg/day for 12 months (n = 45) significantly decreased 
vascular stiffness as assessed by cardio-ankle vascular index 
(CAVI), which was associated significantly with a decrease 
in malondialdehyde-LDL (MDA-LDL).47 These results 
suggest that pitavastatin may produce beneficial effects on 
vasculature.
Coronary artery
From the VH-IVUS analysis, coronary plaques in diabetic 
patients showed increased necrotic core and dense calcium, 
and VHD-TCFA (VH IVUS-derived thin-cap fibroatheroma) 
and VHD-FCA (VH IVUS-derived fibrocalcific atheroma) 
were more frequently observed in diabetic patients than in 
nondiabetic patients.48 In another pooled analysis, coronary 
plaque build-up was more progressive in diabetic patients 
than in nondiabetic patients.49
The JAPAN-ACS study was a randomized prospective 
study with blind endpoint evaluation in Japanese acute 
coronary syndrome (ACS) patients, to evaluate the effect 
of pitavastatin 4 mg/day (n = 125) or atorvastatin 20 mg/
day (n = 127) on coronary artery plaques as assessed by 
intravascular ultrasound.50 After 8–12 months treatment, the 
coronary plaque volume significantly decreased by 16.9% in 
the pitavastatin group and 18.1% in the atorvastatin group, 
suggesting pitavastatin was comparable to atorvastatin 
(Figure 5). In a subanalysis of the JAPAN-ACS study to 
compare diabetic patients with nondiabetic patients, changes 
in coronary plaque volume were significantly associated with 
the reduction of LDL cholesterol in diabetic patients, whereas 
this relationship was not observed in nondiabetic patients.20 
In another subanalysis of JAPAN-ACS study, diabetic ACS 
patients showed greater coronary plaque regression than 
total ACS patients after intensive LDL cholesterol lowering 
therapy.51 In another study to compare pitavastatin 2 mg/day 
(n = 80) with atorvastatin 10 mg/day (n = 80) in ACS patients, 
only pitavastatin 2 mg/day produced significant regression 
of coronary artery plaque volume in 2–3 weeks.52
In the prevention of coronary artery diseases, plaque sta-
bilization is another therapeutic target in addition to plaque 
regression. Yellow color in coronary atheromas as assessed by 
angioscopy was reported to be an indicator of plaque rupture 
risk, and diabetic patients were reportedly more likely to 
have higher yellow color grades than nondiabetics.53 In the 
TOGETHAR trial which evaluated the effects of pitavastatin 
on coronary plaque stabilization using angioscopy and IVUS, 
pitavastatin 2 mg/day (n = 46) significantly reduced the yel-
low grade from 2.9 to 2.6 after 52 weeks’ treatment.54
Carotid artery
Effects of pitavastatin on carotid plaques were assessed by 
measuring plaque echolucency using carotid ultrasound 
with integrated backscatter (IBS) analysis.55 In patients with 
ACS, pitavastatin 4 mg/day (n = 33) significantly improved 
the carotid plaque echolucency within 1 month of therapy; 
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pitavastatin improved the calibrated IBS value from −18.7 
to −12.7 dB, which was almost the same value obtained 
in patients with stable coronary artery disease: −13.2 dB 
(n = 32). Echolucent carotid plaques with low IBS value 
were reported to be associated with future coronary events 
in patients with coronary artery disease56 and pitavastatin 
may be useful in preventing coronary events by stabilizing 
plaques. In addition to plaque characteristics, two ongoing tri-
als, PEACE (UMIN 000001229, NCT 00711919) and NTPP 
(UMIN C000000328), will clarify the effect of pitavastatin 
on carotid intima-media thickness, and another ongoing trial, 
EPOCH-CAS (UMIN 000004113), will examine the effect 
of pitavastatin on perioperative ischemic complications after 
carotid artery stenting.
Kidney
Accumulating evidence suggests that renal dysfunction 
promotes the development of cardiovascular diseases. For 
example, from a recent meta-analysis, low estimated glom-
erular filtration rate (eGFR) of less than 60 mL/min/1.73 m2, 
and high urine albumin-to-creatinine ratio (ACR) of 10 mg/g 
or more were independent predictors of all-cause mortality 
and cardiovascular mortality in the general population.57 
These findings have stimulated interest in the potential effects 
of statin treatment on kidney function, or other surrogate 
markers related to tubuloglomerular damage.
In the LIVES Study subanalysis, pitavastatin 1–4 mg/day 
significantly increased eGFR from 47.8 to 53.2 mL/min/1.73 m2 
over 104 weeks in patients with a baseline eGFR less than 
60 mL/min/1.73 m2 (n = 958) (Figure 6). Using multivariate 
analysis in the LIVES Study, proteinuria and HDL cholesterol 
were negatively and positively   associated with increased 
eGFR, respectively.58 In the GREACE study, various statin 
treatments (mainly atorvastatin) over 3 years significantly 
increased eGFR by 9.8% (P , 0.0001, n = 880). Multiple 
regression analysis showed that every 5% statin-induced 
HDL cholesterol increase significantly and independently 
contributed to eGFR improvement.59 Furthermore, in patients 
with early diabetic nephropathy, pitavastatin 1 mg/day 
(n = 10) significantly reduced urinary albumin excretion and 
urinary liver-type fatty acid-binding protein (L-FABP), which 
reflected the extent of tubulointerstitial damage.60
The precise mechanism underlying renal protection by 
statins remains unknown. Moorhead et al proposed that 
chronic progressive kidney disease may be mediated by 
abnormalities of lipid metabolism.61,62 Several other reports 
have proposed potential explanations. Firstly, as observed in 
the LIVES Study, HDL cholesterol showed a positive asso-
ciation with increasing eGFR,58 which suggests the possibility 
that the antioxidant properties of HDL cholesterol may play 
a role in eGFR increase. Paraoxonase 1 (PON1) is known to 
be located on HDL particles and to inhibit the oxidation of 
LDL and HDL.63 Pitavastatin activates transcription of the 
PON1 gene,64 and this may lead to antioxidization which 
improves endothelial function, and thus renal function. In 
Imai rats, used as a model of focal segmental glomeruloscle-
rosis (FSGS), pitavastatin prevented renal injuries, and lag 
times for LDL and HDL oxidation were prolonged by the 
treatment of pitavastatin.65 Secondly, pitavastatin suppresses 
glomerular mesangial cell proliferation by blocking Ras pro-
cessing and MAP kinase activation.66 Thirdly, pitavastatin is 
reported to cause upregulation of the SLCO4C1 transporter, 
which eliminates uremic toxins. This could provide a novel 
therapeutic potential for statins in chronic kidney disease 
(CKD) patients, if future studies support this idea.67
Cardiovascular event
In the JAPAN-ACS study, major adverse cardiac events 
(MACE) were evaluated prospectively.50 There was no 
significant difference in MACE; 20.4% in pitavastatin 
4 mg/day group and 22.8% in atorvastatin 20 mg/day group. 
In the JAPAN-ACS subanalysis of patients with diabetes 
mellitus, the rate of MACE was 29.9% in diabetic patients, 
which was significantly greater than that in nondiabetic 
patients (18.2%).20
Anti-inflammatory effect and antioxidant effect
C-reactive protein (CRP) is an important risk marker for 
atherosclerotic cardiovascular disease. In the PROVE IT-
TIMI22 Study, ACS patients who have low CRP levels 
after statin therapy have better clinical outcomes than those 
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with higher CRP levels, regardless of the resultant level of 
LDL cholesterol.68 In the Hisayama Study, in which a total 
of 2,589 Japanese participants aged 40 years or older were 
followed up for 14 years, the risk of coronary heart disease 
in the highest quartile group of high-sensitivity CRP (hsCRP) 
levels was 2.98-fold higher than that in the lowest group 
even after controlling for other cardiovascular risk factors.69 
In the JUPITER Trial, rosuvastatin significantly reduced the 
incidence of major cardiovascular events in healthy persons 
with elevated hsCRP.70 Moreover, in some studies, elevated 
hsCRP was reported to be a predictor of the development 
of diabetes.71,72 Anti-inflammatory effects may be important 
in preventing not only cardiovascular disease but also the 
onset of diabetes.
In the KISHIMEN Trial, administration of pitavastatin 
1–2 mg/day for 12 months significantly decreased hsCRP 
by 34.8% (from 0.69 to 0.45 mg/L) in Japanese subjects 
with hypercholesterolemia (n = 31).73 In another small trial, 
administration of pitavastatin 4 mg/day for 1 month signifi-
cantly decreased hsCRP from 0.64 to 0.28 mg/dL in Japanese 
ACS patients (n = 33).55
Anti-oxidant effect is another important factor in prevent-
ing cardiovascular disease and diabetes mellitus. Oxidized 
LDL plays a key role in the initiation and development of 
atherosclerosis.74–76 In Japanese type 2 diabetic patients, 
an inverse correlation between 8-hydroxydeoxyguanosine 
(8-OHdG) positive islet beta-cells and beta-cell volume 
density was observed.77 Pitavastatin 2 mg/day for 12 months 
(n = 45) significantly decreased urinary 8-OHdG excretion 
from 11.3 to 8.4 ng/mg Cr (P , 0.05) and serum MDA-LDL 
levels from 170 to 114 U/L (P , 0.01) in type 2 diabetic 
patients.47 Also pitavastatin 2 mg/day for 6 months (n = 25) 
significantly decreased circulating ligand for lectin-like 
oxidized LDL receptor-1 (LOX-1), a receptor for oxidized 
LDL expressing in vascular endothelial cells, from 867 to 
435 ng/mL (P , 0.0001).78
improving insulin resistance
In the WOSCOPS subanalysis, pravastatin reduced the onset 
of diabetes by 30%, suggesting its beneficial influence on 
glucose tolerance.79 Some reports suggested that pitavas-
tatin improved insulin resistance. Pitavastatin increased 
glucose uptake in KKAy mice,80 and the response to intra-
peritoneal insulin was greater in the pitavastatin-treated 
mice than in the untreated KKAy mice.81 Also, pitavastatin 
improved HOMA-R in type 2 diabetic patients (n = 31) after 
6 month treatment.82 A recent study suggested that HDL 
particle improved glucose metabolism in patients with type 
2 diabetes.83 Thirteen patients with type 2 diabetes were 
treated for 4 hours with intravenous reconstituted HDL 
(rHDL) and placebo in a double-blind, placebo-controlled 
crossover study. Plasma glucose and plasma insulin were 
reduced and increased more, respectively, during the rHDL 
period than during the placebo period. Also, both HDL and 
ApoA-1 increased glucose uptake in primary human skeletal 
muscle cell cultures established from patients with type 2 
diabetic patients. These findings suggest that HDL may be 
associated with improving insulin resistance. The potential 
of pitavastatin to increase HDL cholesterol and ApoA-1 in a 
long-term treatment may be useful not only in preventing car-
diovascular disease but also in improving insulin resistance. 
From this viewpoint, the Japan Prevention Trial of Diabetes 
by Pitavastatin in Patients with Impaired Glucose Tolerance 
(J-PREDICT) study (n = 1240), which examines the preven-
tative effects of pitavastatin plus lifestyle modification on the 
development of new-onset diabetes in Japanese patients with 
impaired glucose tolerance (IGT), is now underway.
Safety
effects on glucose metabolism
Effects of statins on glucose metabolism are an issue cur-
rently under debate.84,85 For example, in the JUPITER trial, 
rosuvastatin significantly prevented vascular events in 
men and women with elevated hsCRP, but increased the 
incidence of new-onset diabetes more than the placebo.70 
A meta-analysis showed that statin therapy was associated 
with a significantly increased risk (9%) of the development 
of diabetes, and meta-regression analysis showed that the 
risk of development of diabetes with statins was highest in 
trials with older participants irrespective of baseline body-
mass index or magnitude of LDL cholesterol reduction.86 
However, this study also suggested that the increment of risk 
remained small both in absolute value and in comparison 
with coronary event reduction, and that clinical practice in 
patients with moderate or high cardiovascular risk or existing 
cardiovascular disease should not be changed.
The advantage of pitavastatin for dyslipidemia in dia-
betic patients is that pitavastatin hardly influences glycemic 
  control. In the CHIBA Study subanalysis of diabetic patients, 
atorvastatin 10 mg/day (n = 22) significantly increased 
glycoalbumin, but pitavastatin 2 mg/day (n = 23) had no 
significant influence on fasting plasma glucose, HbA1c, 
insulin, glycoalbumin, or HOMA-R.87 In another retrospec-
tive analysis to compare the effects of atorvastatin 10 mg/
day (n = 74), pravastatin 10 mg/day (n = 70), and pitavastatin 
2 mg/day (n = 76) on glycemic control during a 3-month Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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  treatment period, only atorvastatin significantly increased 
plasma glucose (from 147 to 176 mg/dL) and HbA1c 
(from 7.0 to 7.4%). Neither pravastatin nor pitavastatin had 
any significant influence on plasma glucose and HbA1c 
(Figure 7).88 Pitavastatin significantly decreased HbA1c in 
diabetic patients in the LIVES Study (n = 308) (Figure 8).89 
Although concomitant antidiabetic therapy was continued in 
the LIVES Study, pitavastatin at least produced no adverse 
effects on glycemic control in diabetic patients in real clini-
cal settings.
The mechanisms by which some statins have adverse 
effects on glycemic control remain uncertain, but one of the 
possible explanations is related to interference with glucose 
transporter-4 (GLUT4). In 3T3-L1 adipocytes, atorvastatin 
significantly prevented translocation of GLUT 4 into the 
plasma membrane, as compared to pravastatin.90 Another 
study examined the effects of statins on glucose uptake using 
3T3-L1 cells. Treatment with atorvastatin attenuated glucose 
transporter-4 (SLC2A4) and C/EBPα expressions in differ-
entiated 3T3-L1 adipocytes. Also atorvastatin 1–10 ng/mL 
significantly decreased glucose uptake in   differentiated 
3T3-L1 cells, but pitavastatin 102 ng/mL did not produce 
any influence.91 These differences across several kinds of 
statins are of great interest and should be confirmed by 
further studies.
Drug–drug interaction
Patients treated with statins usually take a number of drugs, 
and therefore the possibility of drug–drug interactions is an 
issue to be considered when they are prescribed. Atorvastatin 
and simvastatin are known to be metabolized by CYP3A4, 
but pitavastatin is hardly metabolized through this system at 
all (only slightly metabolized by CYP2C9).4,92 For example, 
diabetic patients often have nail ringworm and take antifungal 
agents such as itraconazole. Combined administration of 
itraconazole with CYP3A4-metabolized statin may result in 
an increased concentration of statin due to strong inhibition 
of CYP3A4 by itraconazole.
One example is related to grapefruit juice (GFJ), which 
is known to inhibit CYP3A4. When atorvastatin was taken 
with GFJ, the mean AUC0–24 of atorvastatin acid significantly 
increased by 83%, compared to taking atorvastatin with 
water. By contrast, AUC0–24 of pitavastatin remained similar 
  irrespective of concomitant GFJ or water,93 which would be a 
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Figure 7 Changes in fasting plasma glucose and HbA1c before and after administration of pravastatin 10 mg/day (n = 70), atorvastatin (n = 74), and pitavastatin (n = 76) in 
patients with type 2 diabetes mellitus.
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clinical advantage for pitavastatin. Warfarin is another drug that 
is of concern. CYP2C9 is the primary enzyme in S-warfarin 
metabolism. Assessing the effects of pitavastatin 4 mg/day 
on steady-state warfarin in healthy volunteers (n = 24), the 
ratios of the least squares mean of prothrombin time (PT) and 
international normalized ratio (INR) between the monotherapy 
of warfarin and the concomitant treatment of warfarin and 
pitavastatin were 0.989 and 0.993, respectively, and the 90% 
confidence intervals (CIs) were 0.955 to 1.023 for PT and 0.956 
to 1.029 for INR.94 In this study, no drug–drug interaction 
between pitavastatin and warfarin was demonstrated.
Adverse event rate
Statin treatment usually requires long-term administration, 
and therefore the safety profile is one of the most important 
factors when considering which kind of statins should be pre-
scribed. In the LIVES Study, approximately 20,000   Japanese 
patients with hypercholesterolemia or familial hypercholes-
terolemia were treated for 2 years in order to analyze drug 
safety and effectiveness. The incidence of adverse drug 
reactions was 6.1% (1,206/19,921 patients) after 3 months 
of pitavastatin treatment,19 8.8% (1,753/19,925 patients) after 
1 year of treatment,95 and 10.4% (2,069/19,925 patients) 
after 2 years of treatment.96 For other types of statin treat-
ment used in Japan, the incidence of adverse drug reactions 
was 12.0% (576/4,805 patients) at 3 months of atorvastatin 
treatment,97 and 11.1% (978/8,795 patients) at 3 months of 
rosuvastatin treatment,98 both of which were about twice 
that of pitavastatin. Looking at laboratory data abnormalities 
during a 3 month post-marketing survey of each statin, the 
incidence of CK elevation was 1.41% (pitavastatin), 2.19% 
(atorvastatin), and 2.29% (rosuvastatin); the incidence of 
AST elevation was 0.71% (pitavastatin), 1.14% (atorvas-
tatin), and 0.53% (rosuvastatin); the incidence of ALT 
elevation was 0.90% (pitavastatin), 1.83% (atorvastatin), 
and 0.69% (rosuvastatin); and the incidence of myalgia 
was 0.66% (pitavastatin), 0.50% (atorvastatin), and 1.43% 
(rosuvastatin). In another report from the Japanese Society of 
Hospital Pharmacists, the incidence of suspicious myopathy 
was 0.38% (4/1040) for simvastatin, 0.53% (17/3229) for 
pravastatin, 0.50% (22/4440) for atorvastatin, 0.58% (2/347) 
for fluvastatin, 0.36% (3/838) for pitavastatin, and 1.01% 
(9/891) for rosuvastatin.99
One of the possible explanations why pitavastatin is asso-
ciated with a lower incidence of adverse reactions than other 
potent statins is that pitavastatin can reduce LDL cholesterol 
effectively and safely without blocking the mevalonate 
pathway excessively and in turn inducing LDL receptors. 
When HepG2 cells were treated with a 200-fold excess of the 
IC50 concentration of three HMG-CoA reductase inhibitors 
(pitavastatin, atorvastatin, and simvastatin), pitavastatin was 
able to induce LDL receptor mRNA most effectively.7 This 
suggests that pitavastatin could have the additional capabil-
ity to enhance LDL receptor gene expression, unrelated to 
HMG-CoA reductase inhibition. Interestingly, a crossover 
study comparing pitavastatin 4 mg/day with atorvastatin 
20 mg/day showed that plasma levels of CoQ10 were reduced 
by atorvastatin (−26.1%, P = 0.0007) but not by pitavastatin 
(−7.7%, P = 0.39).100
The relationship between statin-related adverse effects 
and the hepatic drug transporter SLCO1B1 genetic variants 
has been reported. In the SEARCH Study, common vari-
ants in SLCO1B1 were associated with an increased risk of 
statin-induced myopathy, and the odds ratio for myopathy 
was 4.5 per copy of the rs4149056 C allele and 16.9 in CC as 
compared with TT homozygotes.101 Also in the STRENGTH 
Study, SLCO1B1*5 genotype and female sex were associated 
with mild statin-induced adverse effects.102 The influence of 
this genetic variant on pitavastatin-related myopathy should 
be investigated in future studies.
Ongoing pitavastatin trials
Additional trials to test the clinical efficacy of pitavastatin 
in various settings are now underway, and are expected to 
provide further data.
ReAL-CAD (n = 12,600)
REAL-CAD (Randomized Evaluation of Aggressive or Mod-
erate Lipid Lowering Therapy with Pitavastatin in Coronary 
Artery Disease, NCT 01042730, UMIN 000002680) is a trial to 
evaluate the prevention of cardiovascular disease by standard 
cholesterol lowering (pitavastatin 1 mg/day) or   aggressive 
cholesterol lowering (pitavastatin 4 mg/day) in patients with 
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Figure 8 Changes in HbA1c before and after administration of pitavastatin 1–4 mg/day 
in the LiveS study in patients with diabetes mellitus.
Adapted from Teramoto et al.89Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
293
Pitavastatin for diabetes mellitus
stable coronary artery disease. Several large-scale trials such 
as TNT, A-to-Z, IDEAL and PROVE-IT elucidated the 
efficacy of aggressive cholesterol lowering for secondary 
cardiovascular event reduction, and a meta-analysis showed 
that intensive lipid lowering with high-dose statin therapy 
showed a significant (16%) reduction of odds ratio in the risk 
of coronary death or myocardial infarction.103 Although target 
LDL cholesterol for patients with coronary artery disease is 
below 100 mg/dL in the guidelines of the Japan Atherosclero-
sis Society, REAL-CAD will provide important information 
about whether more aggressive cholesterol lowering therapy 
is beneficial, especially in diabetic subjects.
PeARL study (n = 577)
PEARL Study (Pitavastatin Heart Failure Study, UMIN 
C000000428) is a comparative and randomized trial to evalu-
ate the effects of pitavastatin 2 mg/day on cardiac death and 
hospitalization for worsening heart failure in patients with 
mild-to-moderate heart failure.104 Although early studies 
suggested that statins improve cardiac function, CORONA 
and GISSI-HF failed to demonstrate the benefit of rosuvas-
tatin therapy in primary endpoints in patients with heart 
failure,105,106 and the effects of statins on cardiac function 
have remained controversial.
In a small study (n = 23), administration of pitavasta-
tin 1–2 mg/day for 7.5 months significantly increased left 
ventricular ejection fraction (LVEF) from 42 to 48%, and 
significantly decreased the plasma brain natriuretic peptide 
(BNP) level from 94 to 70 pg/mL.107 It has also been reported 
that there was an inverse correlation between atorvastatin-
induced changes in CoQ10 and BNP,108 that CoQ10 level 
was an independent predictor of mortality in chronic heart 
failure,109 and that the CoQ10 level in myocardial tissue was 
lower in patients of NYHA class IV than in patients of NYHA 
class I.110 Considering that pitavastatin does not reduce 
CoQ10 and is effective in improving vascular function, the 
results of PEARL Study may be expected to provide new 
evidence for heart failure treatment with statins.
J-PReDiCT (n = 1,240)
J-PREDICT (Japan Prevention Trial of Diabetes by Pitavas-
tatin in Patients With Impaired Glucose Tolerance, NCT 
00301392, UMIN C000000394) is a comparative and ran-
domized trial to evaluate the prevention of new-onset diabetes 
using pitavastatin 1–4 mg/day in patients with impaired 
glucose tolerance (IGT). This will provide a new possibility 
for the use of statins to control glucose metabolism and the 
development of diabetes.
DiALYSiS (n = 1,550)
DIALYSIS (Differential Intervention Trial by Standard 
Therapy Versus Pitavastatin in Patients With Chronic Hemo-
dialysis, NCT 00846118) is a trial to evaluate the effects 
of pitavastatin 1–4 mg/day on all-cause mortality and the 
incidence of myocardial infarction in hemodialysis patients. 
In Japan, the primary reason for dialysis is diabetic neph-
ropathy, but few trials have evaluated the effects of statins 
on cardiovascular diseases in dialyzed patients. In a 4D trial 
by atorvastatin111 and AURORA by rosuvastatin,112 statin 
therapy did not show any benefit on the primary endpoint 
such as cardiovascular disease or all-cause mortality. How-
ever, in 4D subanalysis, atorvastatin treatment led to a 46% 
risk reduction of all composite cardiovascular endpoints, a 
52% decrease of sudden cardiac death, and a 28% decrease 
of all-cause mortality among patients in the highest LDL 
cholesterol quartile (greater than 145 mg/dL).113 DIALYSIS 
is expected to provide the first evidence of statin use in Asian 
patients with hemodialysis.
TOHO-LiP (n = 600)
TOHO-LIP (TOHO lipid intervention trial using Pitavastatin, 
UMIN 000001404) is a trial to evaluate the prevention of 
various macrovascular diseases by pitavastatin or atorvastatin 
in subjects at high risk of cardiovascular disease. Although 
pitavastatin 2 mg/day and atorvastatin 10 mg/day are gener-
ally considered to show similar LDL cholesterol lowering 
effects, it has also been reported that pitavastatin 2 mg/day 
is superior to atorvastatin 10 mg/day in LDL cholesterol 
lowering in metabolic syndrome patients.22 Therefore, a 
comparative study using pitavastatin and atorvastatin in 
specific patient populations is of interest.
extended-JAPAN-ACS (n = 252)
The Extended-JAPAN-ACS (Extended Japan Assessment of 
Pitavastatin and Atorvastatin in Acute Coronary Syndrome, 
NCT 01223586, UMIN 000003166) trial was carried out to 
verify the relationship between coronary plaque regression and 
cardiovascular events in long-term follow-up in ACS patients 
enrolled in JAPAN-ACS. There are few reports which eluci-
date the relationship between coronary artery plaque regres-
sion and cardiovascular event reduction,114 and therefore the 
Extended-JAPAN-ACS trial could add further evidence useful 
for secondary prevention in the Japanese population.
Prospects and conclusion
Based on these findings, pitavastatin has a number of 
favorable characteristics that are beneficial in patients with Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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diabetes mellitus, which are derived from its efficacy and 
safety; potency in LDL cholesterol reduction; sustained 
HDL cholesterol raising effect; beneficial vascular effects; 
anti-inflammatory and antioxidant effects; improvement of 
insulin resistance; minimal influence on glucose metabolism; 
minimal drug–drug interaction; and low incidence of adverse 
effects. The maximum dose of pitavastatin allowed in Japan 
is 4 mg/day, and it reduces LDL cholesterol by 47%. Judging 
from the unique characteristics of pitavastatin as reviewed in 
this article, this Japanese-oriented statin could provide alter-
native treatment choice especially in patients with glucose 
intolerance or diabetes mellitus.
Considering very recent publications about experimen-
tal studies using nanoparticle (NP)-mediated delivery of 
pitavastatin in limb ischemia models115,116 and pulmonary 
artery hypertension models,117 information is likely to be 
obtained from current clinical trials that will expand the 
possible applications of pitavastatin.
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